Schering Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Consumer Care Ag

Bayer Pharma Aktiengessellschaft

Bernard Jacques Haendler

Joachim Kuhnke

Benjamin Bader

Wolf-Dieter Schleuning

Alejandro Alagon

Christiane Noeske-Jungblut

Lourival Possani

Norbert Schmees

Joern Reiner Kraetzschmar

Arwed Cleve

Roland Neuhaus

Volker Schulze

Ursula Mönning

Ingo Hartung

Amaury Ernesto Fernandez-Montalvan

Pascale Lejeune

Simon Holton

Holger Hess-Stumpp

Detlef Stöckigt

Stephan Siegel

Werner Boidol

Niels Böhnke

Peter Donner

Delia Cuevas-Aguirre

Bertram Weiss

Martin Krüger

Gernot Langer

Daniel Gallenkamp

Matthias Busemann

Stefan Bäurle

Berthold Baldus

Hermann Künzer

Andreas Becker

Elke Winterhager

Simone Scotti

Sabine Krause

Jorn Reiner Kratzschmar

Delia Cuevas-Aguierre

Ulrike Hechler

Christoph Geserick

Berrholt Kreft

Joern Kraetzschmar

Pedro Regidor

Richard Alexander Bouglas

Florian Pühler

Richard Alexander Bissell

Hermann KÜNZER

The present invention relates to: &#x2022; combinations of: * a component A: which is a PI3K kinase inhibitor, such as copanlisib, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same, for example; * a component B: which is an androgen receptor antagonist, such as darolutamide or enzalutamide for example; and, optionally, * one or more pharmaceutical agents C; in which optionally either or both of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially; &#x2022; use of such combinations: * in the treatment or prophylaxis of a cancer, particularly prostate cancer, or * for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly prostate cancer; &#x2022; methods of treatment or prophylaxis of a cancer, particularly prostate cancer, in a subject, comprising administering to said subject a therapeutically effective amount of such a combination; &#x2022; compositions containing such a combination, together with pharmaceutically acceptable ingredients; and &#x2022; kits comprising such a combination.

Combination of a PI3K-inhibitor with an androgen receptor antagonist

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R, R, R, R, R, R, R, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

2,3-benzodiazepines

The present invention relates to BET-protein-inhibitory, in particular BRD4-inhibitory 5-aryltriazoloazepines of the general formula (I) in which R, R, Rand Rhave the meanings given for the general formula (I),to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.

BET protein-inhibiting 5-aryltriazoleazepines

The invention relates to the human PEM polypeptide that plays an important role for the maturation of sperm and for Alzheimer's disease, and the nucleic acid that codes for them. The invention comprises the use of PEM as a target in male birth control and for the treatment and diagnosis of male infertility and Alzheimer's disease. The invention also includes a selection process for PEM antagonists as well as the production of binding molecules, which specifically detect PEM. In addition, genes that are regulated by the PEM gene are part of this invention.

Human PEM as a target for birth control and treatment of Alzheimer's disease

The invention relates to a method for diagnosis of endometriosis, whereby the amount of gene product of at least one gene from the group that consists of fibronectin, insulin-like growth factor binding protein-2, transmembrane receptor PTK7, platelet-derived growth factor receptor alpha, collagen type XVIII alpha 1, subtilisin-like protein (PACE4), laminin M chain (merosin), elastin, collagen type IV alpha 2, p27 interferon alpha-inducible gene, reticulocalbin, aldehyde dehydrogenase 6, gravin, nidogen and phospholipase C epsilon is determined in a patient sample.

Method for in vitro diagnosis of endometriosis

The present invention relates to novel thrombolitic v-PA's which dissolve blood clots in the human body and thus are suitable for the treatment of cardial infarction, for example.

Plasminogen activator from saliva of the vampire bat

Process for manufacture of a modified collagen-induced platelet

Thrombin inhibitor from the saliva of protostomia

The invention provides a protein which inhibits collagen-induced platelet aggregation, derived from Triatoma pallidipennis, and derivatives thereof. The protein is useful for inhibition of collagen-induced human platelet aggregation or of cancer with metastatic tumor cells.

Collagen-induced platelet aggregation inhibitor

Growing community of inventors

Berlin, Germany

Bernard Jacques Haendler